Govt Extends Deadline for Small and Medium Pharma Manufacturers to Comply with Revised Schedule M

The implementation of the revised Schedule M marks a critical step towards enhancing the quality and safety of pharmaceutical products manufactured in India.

The Ministry of Health & Family Welfare has announced a conditional extension for small and medium pharmaceutical manufacturers to comply with the revised Schedule M (Good Manufacturing Practices provisions). Manufacturers with an annual turnover of ₹250 crores or less now have until 31st December, 2025 to meet the updated regulatory standards.

On 28th December, 2023, the Government of India notified significant revisions to Schedule M, enhancing "Good Manufacturing Practices" (GMP) to include detailed requirements of plant and equipment for pharmaceutical products. The amendments aim to align Indian pharmaceutical manufacturing practices with international quality and safety standards.

Categorization and Initial Compliance Deadlines

The revised Schedule M requirements categorized manufacturers into two groups:

1. Large Manufacturers: Companies with a turnover exceeding ₹250 crores were required to comply within 6 months of the notification, with the deadline set for 28th June, 2024.

2. Small and Medium Manufacturers: Companies with a turnover of ₹250 crores or less were initially given 12 months to comply, setting their original deadline for 28th December, 2024.

Conditional Extension for Small and Medium Manufacturers

Following representations from small and medium manufacturers citing the need for additional time to upgrade infrastructure, train personnel, and arrange financial resources, the government has considered their request favorably.

• Submission Requirement: These manufacturers must submit a detailed Plan for Upgradation in Form A to the Central License Approving Authority by 11th May, 2025 (three months from 11th February, 2025).

• Extension Timeline: Upon submission of the plan, the compliance deadline will be extended to 31st December 2025.

Impact and Importance of Revised Schedule M

The implementation of the revised Schedule M marks a critical step towards enhancing the quality and safety of pharmaceutical products manufactured in India. By enforcing stricter GMP and infrastructure requirements, the government aims to:

• Strengthen Domestic Pharmaceutical Standards: Ensuring medicines produced domestically meet rigorous safety and quality benchmarks.

• Enhance Global Competitiveness: Positioning Indian pharmaceutical companies to better compete in international markets by aligning with global regulatory standards.

The revised regulations reflect the government's commitment to safeguarding public health while supporting the growth and modernization of the pharmaceutical industry in India.